An update on PCSK9 inhibitors- pharmacokinetics, drug interactions, and toxicity

Area of Science:

• Cardiology
• Pharmacology

Background:

• Atherosclerotic cardiovascular disease (ASCVD) is a growing global health concern.
• Lipid-lowering therapies are crucial for preventing cardiovascular events.
• PCSK9 inhibitors represent a novel therapeutic class with potential benefits and concerns.

Purpose of the Study:

• To review and analyze adverse events associated with PCSK9 inhibitors.
• To provide recommendations for managing patients on PCSK9 inhibitor therapy.
• To assess the safety profile of PCSK9 inhibitors regarding specific adverse events.

Main Methods:

• Literature review of studies investigating PCSK9 inhibitors and adverse events.
• Analysis of data on neurocognitive function, new-onset diabetes, and muscle symptoms.
• Evaluation of evidence from clinical trials and observational studies.

Main Results:

• PCSK9 inhibitors did not demonstrate a significant impact on cognitive function.
• Studies indicate PCSK9 inhibitors do not increase the risk of new-onset diabetes mellitus.
• No evidence links PCSK9 inhibitors to statin-associated muscle symptoms, even in statin-intolerant patients.

Conclusions:

• Current evidence suggests PCSK9 inhibitors are not linked to the investigated adverse events.
• Further long-term trials are recommended to comprehensively assess potential risks.
• PCSK9 inhibitors appear to be a safe option for lipid management in ASCVD patients.